604 related articles for article (PubMed ID: 11654756)
21. DNA banking and informed consent -- part 2.
Weir RF; Horton JR
IRB; 1995; 17(5-6):1-8. PubMed ID: 11653356
[No Abstract] [Full Text] [Related]
22. Ethics of clinical trials for research ethics boards: proceedings of a national workshop.
National Council on Bioethics in Human Research (Canada)
NCBHR Commun; 1991; 2(2):4-23. PubMed ID: 11659919
[No Abstract] [Full Text] [Related]
23. Pharmacological and psychological research on AIDS: some ethical considerations.
Perry SW
IRB; 1987; 9(5):8-10. PubMed ID: 11649899
[No Abstract] [Full Text] [Related]
24. Informed consent process is deemed "legally and ethically invalid" by witness.
Maloney DM
Hum Res Rep; 1995 Jan; 10(1):4-5. PubMed ID: 11660008
[No Abstract] [Full Text] [Related]
25. Profiting from patient tissue: can patients lay claim to profits from products derived from their tissues?
Med World News; 1985 Jun; 26(11):63. PubMed ID: 11645555
[No Abstract] [Full Text] [Related]
26. Playing roulette with experimental drugs.
Budiansky S
US News World Rep; 1987 Jul; 103(2):58-9. PubMed ID: 11658841
[No Abstract] [Full Text] [Related]
27. Controlling conflicts of interest in the doctor-patient relationship: lessons from Moore v. Regents of the University of California.
Healey JM; Dowling KL
Mercer Law Rev; 1991; 42(3):989-1005. PubMed ID: 11651440
[No Abstract] [Full Text] [Related]
28. Ethics review in Canada: highlights from a national workshop, part 2.
Miller JN
Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):29-33. PubMed ID: 11650304
[No Abstract] [Full Text] [Related]
29. Biotechnology, patients' rights, and the Moore case.
Howard JJ
Food Drug Cosmet Law J; 1989 Jul; 44(4):331-58. PubMed ID: 11659209
[No Abstract] [Full Text] [Related]
30. Money is putting people at risk in biomedical research.
Andrews LB
Chron High Educ; 2000 Mar; 46(27):B1, B4-5. PubMed ID: 11657699
[No Abstract] [Full Text] [Related]
31. Rate of refusal to participate in clinical trials.
Shimm DS; Spece RG
IRB; 1992; 14(2):7-9. PubMed ID: 11651246
[No Abstract] [Full Text] [Related]
32. Facilitating ethical research: promoting informed choice.
National Council on Bioethics in Human Research (Canada)
NCBHR Commun; 1996 Dec; 7(2 Suppl):i-1-28. PubMed ID: 11660531
[No Abstract] [Full Text] [Related]
33. Familial coercion to participate in genetic family studies: is there cause for IRB intervention?
Parker LS; Lidz CW
IRB; 1994; 16(1-2):6-12. PubMed ID: 11652324
[No Abstract] [Full Text] [Related]
34. Hyperbaric research at Duke University--ethical considerations.
Bennett PB; Kylstra JA
Forsvarsmedicin; 1973; 9(3):373-8. PubMed ID: 11661280
[No Abstract] [Full Text] [Related]
35. Cells, sales, and royalties: the patient's right to a portion of the profits.
Danforth MT
Yale Law Policy Rev; 1988; 6(1):179-202. PubMed ID: 11650242
[No Abstract] [Full Text] [Related]
36. IRBs and research with human biological materials.
Maloney DM
Hum Res Rep; 1999 Jan; 14(1):2. PubMed ID: 11657556
[No Abstract] [Full Text] [Related]
37. Structuring the review of human genetics protocols, Part II: diagnostic and screening studies.
Glass KC; Weijer C; Lemmens T; Palmour RM; Shapiro SH
IRB; 1997; 19(3-4):1-13. PubMed ID: 11656943
[No Abstract] [Full Text] [Related]
38. Protection of human subjects.
United States
Code Fed Regul Shipping; 1982 Oct; Part 46, Sections 46.101 to 46.306():. PubMed ID: 11660819
[No Abstract] [Full Text] [Related]
39. Adequate protection for the autonomous research subject? The disclosure of sources of funding and commercialisation in genetic research trials.
Cote A
Manit Law J; 2002; 28(3):347-58. PubMed ID: 15162817
[No Abstract] [Full Text] [Related]
40. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
